Sandoz Group (OTCMKTS:SDZNY) Downgraded by UBS Group to Hold

Sandoz Group (OTCMKTS:SDZNY) was downgraded by investment analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Separately, BNP Paribas lowered shares of Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Monday, December 2nd.

Sandoz Group Stock Up 4.1 %

SDZNY opened at $48.61 on Monday. The company has a fifty day moving average price of $43.52 and a two-hundred day moving average price of $43.20. Sandoz Group has a 52 week low of $27.79 and a 52 week high of $48.66.

Sandoz Group Company Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.